Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
pharmaceutical investing Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
pharmaceutical investing Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
